CD4+T cells were increased in fibromyalgia patients with respect to HC. However, only IL17A and IFNγ, but not IL-4 producing CD4+T lymphocytes were increased with respect fibromyalgia secondary to Sjögren. These alterations were due to an increase of Treg in both early and established RA patient subsets in fibromyalgia patients. Furthermore, IFNγ producing CD4+T cells were decreased in fibromyalgia secondary to Sjögren’s with respect to fibromyalgia patients and HC. Counts of Treg TNFα producing CD4+ T cells were increased in fibromyalgia with respect fibromyalgia secondary to Sjögren. IL-10 producing CD4+T cells were normal in fibromyalgia but decreased in fibromyalgia secondary to Sjögren.

**Conclusion:** Fibromyalgia patients show an abnormal circulating activation stages of CD4+ T cells, as well as, express usual elevated counts of CD4+ T cells producing IL-17A, IL-4 and IFNγ. These alterations could differentiate two different pathologic and inflammatory behaviors of the T cell compartment between fibromyalgia and fibromyalgia secondary to Sjögren patients.

**References:**

[2] A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthri-

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5524

**AB0036**

**CHILDREN WITH EXTENDED OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS HAVE A CYTOKINE PATTERN FAVORING B CELL ACTIVATION IN CIRCULATION**

R. A. Moura1, F. Oliveira-Flammos 1, 2, C. Marques1, A. Brito1, R. L. Teixeira1, V. C. Romanò1, R. Campanillo-Marques1, 2, V. Teixeira1, M. J. Saaedara, C. Ponte1, 2, N. Khmelinskii3, E. J. Fonseca1, 2, 3, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; 2Rheumatology Department, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal

**Background:** Juvenile idiopathic arthritis (JIA) is the most common rheu-
matic disease in children. The majority of polyarticular JIA (pJIA) and a large fraction of extended oligoarticular JIA (oJIA) patients fulfill classification cri-
teria for rheumatoid arthritis (RA) in adulthood. B-cells play several impor-
tant roles in RA pathogenesis, but it is still unclear if the pattern of B-cell involvement in pJIA and extended oJIA follows what has been described for adults with RA.

**Objectives:** The main goal of this study was to determine the concentration of cytokines potentially relevant for B-cell activation in serum from children with pJIA and extended oJIA when compared to children with persistent oJIA, adult JIA, early and established RA.

**Methods:** Serum samples were collected from children with extended oJIA (n=8), persistent oJIA (n=6), pJIA (n=6), adult JIA (n=8), untreated early RA (<1 year of disease duration, n=12), established RA patients treated with synthetic disease-modifying anti-rheumatic drugs (DMARDs) (n=10) and two groups of age- and sex-matched healthy children, n=6 and adults, n=10). A prolif-
eration-inducing ligand (APRIL), B-cell activating factor (BAFF), interleukin (IL)-6 and IL-21 serum levels were measured by enzyme-linked immunosorbent assay (ELISA).

**Results:** Children with extended oJIA, early and established RA patients had significantly higher BAFF serum levels when compared to controls, but no signif-
icient differences were observed in children with persistent oJIA, pJIA and adult JIA when compared to all groups included. APRIL serum levels were signifi-
cantly increased in early and established RA patients when compared to both controls and children with persistent oJIA. No significant differences were found in APRIL concentrations between children with JIA, adult JIA and controls. IL-6 serum levels were significantly increased in children with extended oJIA, pJIA, early and established RA when compared to controls, but no significant differ-
ences were found in children with persistent oJIA and adult JIA patients. IL-21 serum levels were significantly increased in early RA when compared to con-
trols, but no significant differences were observed between any of the other groups included.

**Conclusion:** The similarity in B-cell cytokine pattern found between extended oJIA, pJIA, early and established RA patients, contrarily to what was observed in persistent oJIA, suggests an early B-cell involvement in the pathogenesis of extended oJIA and pJIA as described for RA.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.4895

**AB0037**

**EXPRESSION OF NEGATIVE CHECKPOINT MOLECULES BTLA AND HVEM IS DYSREGULATED IN AUTOIMMUNE DISEASES**

S. Nagpal1, S. Cole1, A. Floudas2, M. Wechalekar3, Q. Song1, T. Gordon4, R. Caricchio5, D. Veale6, U. Fearon7, N. Rao8, L. Y. Hao9; Janssen Research & Development, Spring House, United States of America; 2Trinity College Dublin, Dublin, Ireland; 3Finders University, Adelaide, Australia; 4Temple University, Philadelphia, United States of America; 9University College Dublin, Dublin, Ireland

**Background:** Immune checkpoint blockade with agents targeting CTLA4 and PD-1/PDL-1 alone or in combination has demonstrated exceptional efficacy in multiple cancer types by "unleashing" the cytotoxic action of quiescent, tumor-
infritating T cells. However, the therapeutic action of these immunotherapies goes hand in hand with the loss of immune tolerance and appearance of immune-related adverse events such as colitis, arthralgia and inflammatory arthritis in responsive patients. Therefore, immune checkpoint molecules have been proposed as targets for the treatment of autoimmune diseases.

**Objectives:** Herein, we interrogate the potential of BTLA/HVEM axis as a target for restoring immune homeostasis in rheumatoid arthritis (RA). Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome (SJS) by examining their expres-
sion patterns in autoimmune disease tissues.

**Methods:** Message and protein expression of BTLA and HVEM were examined in RA and SLE synovial tissues, SLE cutaneous lesions, SJS salivary glands and peripheral blood samples of autoimmune disease by RNA sequencing and flow cytometry.

**Results:** Tissue dysregulation of the BTLA-HVEM axis was observed: Increased BTLA RNA level in RA synovium, SLE-afflicted skin, and SJS salivary gland samples, whereas HVEM level was affected only in the RA synovium when com-
pared to unaffected tissues. Detailed immunophenotyping of B, T, and myeloid cell populations in RA, SLE, SJS and healthy control PBMCs revealed differential modulation of the BTLA+ or HVEM+ immune cell subsets in a disease-context-
dependent manner. SJS patients showed an overall decrease in memory B cells and most of the BTLA+ B cell subsets while a decrease in HVEM+ B cells was observed only in SLE PBMC samples and not RA and SLE samples. Immu-
nophenotyping with a T cell panel exhibited decreased BTLA and HVEM expres-
sion on T cell subsets in SJS and SLE but not in RA patients. In addition, protein levels of HVEM were differentially decreased in SLE myeloid cell subsets. Finally, we demonstrate tissue-specific surface expression patterns of BTLA in RA and SLE samples: higher surface BTLA levels on RA and SLE PBMC B cells than matched tissue-derived B cells.

**Conclusion:** Our results demonstrate a dysregulation of the BTLA/HVEM axis in either lesional tissue or peripheral blood in an autoimmune disease context-
dependent manner. These results also indicate the potential of targeting BTLA-
HVEM axis for the treatment of multiple autoimmune diseases.

**Disclosure of Interests:** Sunil Nagpal Shareholder of: Janssen Pharmaceuti-

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.3347

**AB0038**

**IMMUNE PHENOTYPING OF ERDHEIM-CHESTER DISEASE THROUGH MASS CYTOMETRY**

M. Papp1, 2, A. Corneau1, F. Cohen1, B. Robin3, J. F. Emile1, M. Miyara1, C. Blanc1, Z. Amoura1, O. Hermine2, J. Haroche1, T. Travail Maciei1, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Institut E3M, Centre National de Référence des Histioctoses, Paris, France; 1Imagine Institute, Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, Imagine Institute, INSERM UMR1163, Paris, France; 2Sorbonne Université, INSERM UMS037 PASS, Plateforme de Cytométrie (CyPS), Paris, France; 3Université de Versailles, AP-HP EA4340- BECCOH, Département de Pathologie, Boulogne Billancourt, France; 3Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Centre d’Immunologie et des Maladies Infectieuses (CIMiParis), Ireland

**Background:** Erdheim-Chester disease (ECD) is an uncommon rheu-
matic disorder characterized by a diffuse infiltration of macrophages and histiocytes with eosinophilia and lymphocytic atrophy. The disease is associated with a characteristic CD1a+ cutaneous infiltrate. The diagnosis rests on imaging and tissue biopsy. As ECD is a histiocytic disorder, abnormal expression of negative regulatory molecules like BTLA and HVEM could be involved in the immune response and the mechanisms of immune regulation in ECD.

**Objectives:** Our aim was to study the expression of BTLA and HVEM in patients with ECD, as well as to determine their role in the immune response.

**Methods:** We performed a detailed immune phenotyping of ECD patients and healthy controls. PBMCs were isolated from patients and controls, and the expression of BTLA and HVEM was determined by flow cytometry.

**Results:** We found that patients with ECD had a significantly higher expression of BTLA and HVEM compared to healthy controls. This suggests that these molecules play a role in the immune response in ECD.

**Conclusion:** Our findings support the potential involvement of BTLA and HVEM in the immune response in ECD. Further studies are needed to investigate the mechanisms by which these molecules contribute to the disease.